{"id":4877,"date":"2022-01-12T16:00:00","date_gmt":"2022-01-12T16:00:00","guid":{"rendered":"https:\/\/www.prnasia.com\/story\/archive\/3628639_HK28639_0"},"modified":"2022-01-12T16:00:00","modified_gmt":"2022-01-12T16:00:00","slug":"alar-announces-significant-progress-on-developing-long-acting-buprenorphine-injectable-ala-1000","status":"publish","type":"post","link":"https:\/\/transmediavictoria.net.au\/?p=4877","title":{"rendered":"Alar Announces Significant Progress on Developing Long-acting Buprenorphine Injectable ALA-1000"},"content":{"rendered":"<div id=\"dvContent\" readability=\"89.480266814897\">\n<ul type=\"disc\">\n<li>Single-ascending-dose (SAD) study successfully demonstrated the safety, tolerability, and sustained release profile at least 3 months resulting from ALA-1000 injection in patients with opioid dependence.<\/li>\n<\/ul>\n<p>TAICHUNG, <span class=\"xn-location\">Taiwan<\/span>, <span class=\"xn-chron\">Jan. 13, 2022<\/span> \/PRNewswire\/ &#8212; Alar Pharmaceuticals Inc. (Alar, TWSE:6785), a clinical-stage biopharmaceutical company focused on developing long-acting injectables (LAIs) for central nervous system disorders, announces the completion and positive results of ALA-1000 SAD study (A1-19-P01). The results represent the first demonstration of safety, tolerability, and pharmacokinetic (PK) durability for ALA-1000, a subcutaneous LAI formulation releasing buprenorphine, in patients with opioid use disorder (OUD) administered subcutaneously.<\/p>\n<p>Based on the data of safety assessments, subcutaneous injections of ALA-1000 were well-tolerated in all dose-escalation cohorts. All the drug-related adverse events (AEs) were mild or moderate in severity and were consistent with expected opioid withdrawal and known pharmacology effects of buprenorphine. No significant or unexpected safety findings were identified in this first-in-human study. The injection site reactions were scored as none mostly or mild rarely and resolved within 1 hour mainly. No subjects discontinued the study due to injection site reactions. ALA-1000 achieved anticipated PK profile in human, i.e., consistent buprenorphine-release with therapeutically effective plasma levels for at least 3 months&nbsp;but low fluctuation and without dose dumping, significant initial burst.<\/p>\n<p>The secondary endpoints regarding efficacy demonstrated that patients who received single ALA-1000 injection at target dose remained relatively mild withdrawal signs and symptoms (mean score &lt; 5 on Clinical Opiate Withdrawal Scale [COWS]) and opioid craving (\u2264 14 mm on the Opioid Craving Visual Analog Scale [VAS]), and displayed \u2265 80% negative urine opioids toxicology results during the outpatient phase (up to Day 175).<\/p>\n<p>&#8220;This SAD study demonstrates that ALA-1000 brings sustained releasing profile in various dose strengths, therefore, ALA-1000 can not only provide a new solution for the opioid crisis but can contribute to chronic pain <span id=\"spanHghlt2cb1\">management.&#8221;<\/span> said <span class=\"xn-person\">Yung-Shun Wen<\/span>, CEO of Alar Pharmaceuticals.<\/p>\n<p>&#8220;A breakthrough in developing this new medication for OUD has been made,&#8221; said <span class=\"xn-person\">Charles Lin<\/span>, Founder and Chairman of Alar Pharmaceuticals, &#8220;We firmly believe that these successful clinical outcomes of ALA-1000 support us to accelerate the later clinical development and launching to provide a better choice for patients and physicians. We look forward to working with potential collaboration partners to bring this novel treatment to the patients suffering from OUD.&#8221;<\/p>\n<p>Alar has completed a successful end-of-phase 2 meeting with US FDA for ALA-1000. The phase III pivotal trial to support NDA application is planned to initiate this year.<\/p>\n<p><b>About ALA-1000<\/b><\/p>\n<p>ALA-1000 is the first, three-month Buprenorphine LAI administered subcutaneously entering the clinical stage. The proposed buprenorphine systemic exposure resulting from the ALA-1000 injection remains effective over 3 months per administration and benefits patients by reducing the burden of daily administration, improving patient compliance, and diminishing the concerns of misuse, abuse, and accidental pediatric exposure.<\/p>\n<p>For more information, please visit Alar&#8217;s website at <a target=\"_blank\" href=\"https:\/\/alarpharm.com\/\" rel=\"nofollow noopener\">https:\/\/alarpharm.com\/<\/a><\/p>\n<p id=\"PURL\"><img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=HK28639&amp;sd=2022-01-12\"> View original content:<a id=\"PRNURL\" rel=\"nofollow noopener\" href=\"https:\/\/www.prnewswire.com\/news-releases\/alar-announces-significant-progress-on-developing-long-acting-buprenorphine-injectable-ala-1000-301459457.html\" target=\"_blank\">https:\/\/www.prnewswire.com\/news-releases\/alar-announces-significant-progress-on-developing-long-acting-buprenorphine-injectable-ala-1000-301459457.html<\/a><\/p>\n<\/p><\/div>\n<p>Source: Alar Pharmaceuticals Inc.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Single-ascending-dose (SAD) study successfully demonstrated the safety, tolerability, and sustained release profile at least 3 months resulting from ALA-1000 injection in patients with opioid dependence. TAICHUNG, Taiwan, Jan. 13, 2022 \/PRNewswire\/ &#8212; Alar Pharmaceuticals Inc. (Alar, TWSE:6785), a clinical-stage biopharmaceutical company focused on developing long-acting injectables (LAIs) for central nervous system disorders, announces the completion [&hellip;]<\/p>\n","protected":false},"author":8,"featured_media":4878,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[20],"tags":[],"class_list":["post-4877","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-business-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Alar Announces Significant Progress on Developing Long-acting Buprenorphine Injectable ALA-1000 - My Blog<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/transmediavictoria.net.au\/?p=4877\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Alar Announces Significant Progress on Developing Long-acting Buprenorphine Injectable ALA-1000 - My Blog\" \/>\n<meta property=\"og:description\" content=\"Single-ascending-dose (SAD) study successfully demonstrated the safety, tolerability, and sustained release profile at least 3 months resulting from ALA-1000 injection in patients with opioid dependence. TAICHUNG, Taiwan, Jan. 13, 2022 \/PRNewswire\/ &#8212; Alar Pharmaceuticals Inc. (Alar, TWSE:6785), a clinical-stage biopharmaceutical company focused on developing long-acting injectables (LAIs) for central nervous system disorders, announces the completion [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/transmediavictoria.net.au\/?p=4877\" \/>\n<meta property=\"og:site_name\" content=\"My Blog\" \/>\n<meta property=\"article:published_time\" content=\"2022-01-12T16:00:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/transmediavictoria.net.au\/wp-content\/uploads\/2022\/01\/alar-announces-significant-progress-on-developing-long-acting-buprenorphine-injectable-ala-1000.png\" \/>\n\t<meta property=\"og:image:width\" content=\"16\" \/>\n\t<meta property=\"og:image:height\" content=\"16\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"admin_tony\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin_tony\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=4877#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=4877\"},\"author\":{\"name\":\"admin_tony\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\"},\"headline\":\"Alar Announces Significant Progress on Developing Long-acting Buprenorphine Injectable ALA-1000\",\"datePublished\":\"2022-01-12T16:00:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=4877\"},\"wordCount\":491,\"image\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=4877#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/transmediavictoria.net.au\\\/wp-content\\\/uploads\\\/2022\\\/01\\\/alar-announces-significant-progress-on-developing-long-acting-buprenorphine-injectable-ala-1000.png\",\"articleSection\":[\"Business News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=4877\",\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=4877\",\"name\":\"Alar Announces Significant Progress on Developing Long-acting Buprenorphine Injectable ALA-1000 - My Blog\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=4877#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=4877#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/transmediavictoria.net.au\\\/wp-content\\\/uploads\\\/2022\\\/01\\\/alar-announces-significant-progress-on-developing-long-acting-buprenorphine-injectable-ala-1000.png\",\"datePublished\":\"2022-01-12T16:00:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=4877#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=4877\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=4877#primaryimage\",\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/wp-content\\\/uploads\\\/2022\\\/01\\\/alar-announces-significant-progress-on-developing-long-acting-buprenorphine-injectable-ala-1000.png\",\"contentUrl\":\"https:\\\/\\\/transmediavictoria.net.au\\\/wp-content\\\/uploads\\\/2022\\\/01\\\/alar-announces-significant-progress-on-developing-long-acting-buprenorphine-injectable-ala-1000.png\",\"width\":16,\"height\":16},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=4877#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/transmediavictoria.net.au\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Alar Announces Significant Progress on Developing Long-acting Buprenorphine Injectable ALA-1000\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#website\",\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/\",\"name\":\"My Blog\",\"description\":\"My WordPress Blog\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\",\"name\":\"admin_tony\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"caption\":\"admin_tony\"},\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?author=8\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Alar Announces Significant Progress on Developing Long-acting Buprenorphine Injectable ALA-1000 - My Blog","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/transmediavictoria.net.au\/?p=4877","og_locale":"en_US","og_type":"article","og_title":"Alar Announces Significant Progress on Developing Long-acting Buprenorphine Injectable ALA-1000 - My Blog","og_description":"Single-ascending-dose (SAD) study successfully demonstrated the safety, tolerability, and sustained release profile at least 3 months resulting from ALA-1000 injection in patients with opioid dependence. TAICHUNG, Taiwan, Jan. 13, 2022 \/PRNewswire\/ &#8212; Alar Pharmaceuticals Inc. (Alar, TWSE:6785), a clinical-stage biopharmaceutical company focused on developing long-acting injectables (LAIs) for central nervous system disorders, announces the completion [&hellip;]","og_url":"https:\/\/transmediavictoria.net.au\/?p=4877","og_site_name":"My Blog","article_published_time":"2022-01-12T16:00:00+00:00","og_image":[{"width":16,"height":16,"url":"https:\/\/transmediavictoria.net.au\/wp-content\/uploads\/2022\/01\/alar-announces-significant-progress-on-developing-long-acting-buprenorphine-injectable-ala-1000.png","type":"image\/png"}],"author":"admin_tony","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin_tony","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/transmediavictoria.net.au\/?p=4877#article","isPartOf":{"@id":"https:\/\/transmediavictoria.net.au\/?p=4877"},"author":{"name":"admin_tony","@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7"},"headline":"Alar Announces Significant Progress on Developing Long-acting Buprenorphine Injectable ALA-1000","datePublished":"2022-01-12T16:00:00+00:00","mainEntityOfPage":{"@id":"https:\/\/transmediavictoria.net.au\/?p=4877"},"wordCount":491,"image":{"@id":"https:\/\/transmediavictoria.net.au\/?p=4877#primaryimage"},"thumbnailUrl":"https:\/\/transmediavictoria.net.au\/wp-content\/uploads\/2022\/01\/alar-announces-significant-progress-on-developing-long-acting-buprenorphine-injectable-ala-1000.png","articleSection":["Business News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/transmediavictoria.net.au\/?p=4877","url":"https:\/\/transmediavictoria.net.au\/?p=4877","name":"Alar Announces Significant Progress on Developing Long-acting Buprenorphine Injectable ALA-1000 - My Blog","isPartOf":{"@id":"https:\/\/transmediavictoria.net.au\/#website"},"primaryImageOfPage":{"@id":"https:\/\/transmediavictoria.net.au\/?p=4877#primaryimage"},"image":{"@id":"https:\/\/transmediavictoria.net.au\/?p=4877#primaryimage"},"thumbnailUrl":"https:\/\/transmediavictoria.net.au\/wp-content\/uploads\/2022\/01\/alar-announces-significant-progress-on-developing-long-acting-buprenorphine-injectable-ala-1000.png","datePublished":"2022-01-12T16:00:00+00:00","author":{"@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7"},"breadcrumb":{"@id":"https:\/\/transmediavictoria.net.au\/?p=4877#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/transmediavictoria.net.au\/?p=4877"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/transmediavictoria.net.au\/?p=4877#primaryimage","url":"https:\/\/transmediavictoria.net.au\/wp-content\/uploads\/2022\/01\/alar-announces-significant-progress-on-developing-long-acting-buprenorphine-injectable-ala-1000.png","contentUrl":"https:\/\/transmediavictoria.net.au\/wp-content\/uploads\/2022\/01\/alar-announces-significant-progress-on-developing-long-acting-buprenorphine-injectable-ala-1000.png","width":16,"height":16},{"@type":"BreadcrumbList","@id":"https:\/\/transmediavictoria.net.au\/?p=4877#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/transmediavictoria.net.au\/"},{"@type":"ListItem","position":2,"name":"Alar Announces Significant Progress on Developing Long-acting Buprenorphine Injectable ALA-1000"}]},{"@type":"WebSite","@id":"https:\/\/transmediavictoria.net.au\/#website","url":"https:\/\/transmediavictoria.net.au\/","name":"My Blog","description":"My WordPress Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/transmediavictoria.net.au\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7","name":"admin_tony","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","caption":"admin_tony"},"url":"https:\/\/transmediavictoria.net.au\/?author=8"}]}},"_links":{"self":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts\/4877","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4877"}],"version-history":[{"count":0,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts\/4877\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/media\/4878"}],"wp:attachment":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4877"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4877"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4877"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}